Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term extension study of givinostat in Duchenne muscular dystrophy
MOH_2021-10-20_010343Phase 3Active, not recruiting
- Sponsor
- Italfarmaco
- Start
- Oct 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of givinostat in Duchenne muscular dystrophy (DMD), sponsored by Italfarmaco. Started Oct 2021; status: active, not recruiting.
02
Drugs
givinostat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on MOH_2021-10-20_010343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-10-20_010343.